India, May 19 -- Sensei Biotherapeutics Inc. (SNSE), a clinical-stage biotechnology company, on Friday announced first quarter financial results, and provided updates on its developing pipeline.
Q1 2026:
The company reported a net loss of $170.24 million or $131.45 per share, nearly doubled from the first quarter loss of $6.9 million or $5.45 per share in the previous year. The significant Acquired In-Process Research and Development (IPR&D) expenditures totaling $133 million due to the acquisition of Faeth Therapeutics was the main contributor to the higher losses.
R&D expenses amounted to $17.95 million, while in 2025 the same was $3.72 million. G&A expenses also rose to $19.71 million from $3.55 million reported a year ago. The increa...